$SNEX

Maurer Mark Lowry sold $6.2M of SNEX

Maurer Mark Lowry sold 46,248 shares of StoneX Group Inc. (SNEX) at an average of $134.89 ($133.63–$135.31, $6.24M total) across 2 trades over 2026-06-15 to 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maurer Mark Lowry
Published Jun 17, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNEX
Neutral
high confidence
Mentioned
$SNEX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price range, and post-transaction holdings; there is no new guidance, deal, litigation, or operating update.

02

Market read

Traders may treat this as a small sentiment datapoint, but the 10b5-1 structure reduces the likelihood of a fundamental read-through.

03

What to watch

The filing does not indicate whether other insiders or institutions are buying; traders should check for concurrent insider buys or larger ownership changes.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-17; trades occurred 2026-06-15 to 2026-06-16.

Background

The article is an SEC Form 4 disclosure of an insider’s open-market sale by Maurer Mark Lowry at StoneX Group Inc., executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$SNEXNeutralHigh confidence
Context

StoneX Group insider Maurer Mark Lowry sold 46,248 shares in open-market trades for about $6.24M under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale with a pre-arranged 10b5-1 plan and no accompanying new company-specific operational or financial disclosure.

Market effects

Minimal; this is company-specific insider activity without sector-wide catalyst.

Minimal; no macro/regional linkage beyond general sentiment.

Minimal; no international transaction or regulatory action described.

Counterpoint

10b5-1 sales are often mechanical for liquidity/tax planning, so the market may overreact relative to the true signal.

Key entities

  • StoneX Group Inc.

    Subject of the Form 4 insider transaction; shares sold by insider under a 10b5-1 plan.

  • Maurer Mark Lowry

    Insider who executed the open-market sale of 46,248 shares across two trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WGOMedAI 8/10

Winnebago stock rises as StoneX lowers price target on industry outlook

StoneX lowered its price target on Winnebago (WGO) to $36 from $40, maintaining a Buy rating. The stock trades at $26.83 with a 5.62% dividend yield. Winnebago issued fiscal 2027 guidance for sales of $2.65B-$2.80B and adjusted EPS of $1.65-$2.25, with midpoints above consensus. The company reduced 2026 RV shipment expectations and guided 2027 shipments to 265,000-295,000 units. The stock rose 10.5% on Monday following earnings and guidance.

$MXLMed

MaxLinear stock rating reiterated at Buy by StoneX ahead of results

StoneX reiterated a Buy rating on MaxLinear (MXL) with a $125 price target ahead of its October 22 earnings report. The firm expects Q3 revenue of $215M-$220M, matching consensus. MXL shares are down 20% in a week but up 320% year-to-date. S&P upgraded its outlook to positive, citing strong infrastructure revenue growth. Analysts highlight MXL's potential in the optical market.

$EQBKMed

StoneX lowers Equity Bancshares stock price target on NIM outlook

StoneX reduced its price target for Equity Bancshares (EQBK) to $58 from $59, citing net interest margin expectations. The firm raised its fiscal 2026 EPS forecast to $5.18 but lowered the 2027 estimate to $5.27. EQBK's stock trades at a P/E ratio of 10.58, and analysts expect net income growth. The company recently reported Q3 earnings beating estimates, with EPS of $1.40 vs. $1.29 expected, but revenue missed slightly.